Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Chemomab Therapeutics Ltd - AD - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CMMB
Nasdaq
8731
https://www.chemomab.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Chemomab Therapeutics Ltd - AD
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
- Apr 24th, 2024 11:00 am
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
- Apr 18th, 2024 11:00 am
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
- Apr 2nd, 2024 11:00 am
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
- Mar 25th, 2024 11:06 am
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
- Mar 7th, 2024 12:00 pm
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
- Mar 5th, 2024 12:00 pm
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
- Feb 20th, 2024 12:00 pm
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
- Feb 14th, 2024 12:00 pm
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
- Feb 5th, 2024 12:00 pm
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
- Jan 30th, 2024 12:00 pm
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
- Jan 3rd, 2024 12:00 pm
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
- Nov 16th, 2023 12:00 pm
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
- Nov 15th, 2023 12:00 pm
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver MeetingĀ® 2023
- Nov 13th, 2023 1:00 pm
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 9th, 2023 1:00 pm
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
- Nov 6th, 2023 9:15 pm
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
- Oct 30th, 2023 11:00 am
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
- Oct 26th, 2023 11:00 am
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
- Sep 28th, 2023 11:00 am
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Aug 29th, 2023 11:00 am
Scroll